Provider: - Institution: - Data provided by Europeana Collections- Date de numérisation : 2011- Nombre de vues du document : 2- Partenariats : Document numérisé grâce au mécénat de la Société BIC- ...Fonds ou documents en rapport : Voir tout le fonds d'archives Guichard (Carton 39) - All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: Institut National d'Histoire de l'Art - Data provided by Europeana Collections- s.d.- 18e siècle- Nombre de vues du document : 2- Date de numérisation : 2011- Documents en ...rapport : Voir tous les autographes Guichard (Carton 39)- Partenariats : Document numérisé grâce au mécénat de la Société BIC- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Background
LentiGlobin gene therapy contains autologous CD34+ hematopoietic stem cells (HSCs) transduced with the BB305 lentiviral vector (LVV), encoding human β-globin with a T87Q substitution. This ...substitution confers anti-sickling properties to the gene therapy-derived hemoglobin (HbAT87Q) and allows for its quantification in transduced HSCs. The proof of concept for LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) was established in the recently completed HGB-205 study (NCT02151526). Herein, we provide the safety and efficacy outcomes and long-term follow-up data for all 7 treated patients, 4 with TDT and 3 with SCD.
Methods
Patients 5−35 years old with TDT (≥ 100 mL/kg of packed red blood cells pRBCs/year) or severe SCD (e.g., ≥ 2 acute chest syndromes ACS or ≥ 2 vaso-occlusive crises in the preceding year or the year before regular transfusions) were enrolled. CD34+ HSCs were obtained by mobilization and apheresis in patients with TDT or by bone marrow harvest in patients with SCD. Following collection, cells were transduced with the BB305 LVV. Patients underwent busulfan myeloablative conditioning and were infused with transduced cells. Patients were monitored for engraftment, adverse events (AEs), HbAT87Q levels, and other hematologic and clinical parameters. After 2 years in HGB-205, patients transitioned into the long-term follow-up study, LTF-303 (NCT02633943). Summary statistics are shown as median (min-max).
Results
As of June 2019, patients with TDT (n=4) and SCD (n=3) had a median follow-up of 49.6 (40.5-60.6) and 28.5 (25.5-52.5) months, respectively. Table 1 shows patient and drug product characteristics and several key efficacy outcomes. All patients achieved HSC engraftment. LentiGlobin safety profile was consistent with busulfan myeloablative conditioning and, in case of SCD, with the underlying disease state. The most common non-hematologic Grade ≥ 3 AEs post-LentiGlobin gene therapy (≥ 2 patients) for patients with TDT were stomatitis (n=4) and increased aspartate aminotransferase (n=2), and for patients with SCD were ACS (n=2) and vaso-occlusive pain (n=2).
In all 4 patients with TDT, total Hb and HbAT87Q levels remained generally stable up to 5 years post-LentiGlobin infusion. Three of 4 patients achieved transfusion independence (TI; defined as weighted average Hb ≥ 9g/dL without pRBC transfusions for ≥ 12 months), for an ongoing duration of 56.3 (38.2-57.6) months. Weighted average total Hb during TI was 11.4 (10.5-13.0) g/dL. One patient has been off transfusions for 37.5 months and had total Hb of 7.7 g/dL, which was below the ≥ 9 g/dL requirement to meet the protocol definition of TI. At last visit, HbAT87Q levels in these 4 patients ranged from 6.2-11.2 g/dL, which contributed 73.8-86.8% of the total Hb.
The first patient treated with LentiGlobin for SCD experienced one vaso-occlusive pain episode, which developed at 30 months after LentiGlobin gene therapy following a case of acute gastroenteritis with fever and dehydration. The second SCD patient had 2 serious AEs (SAEs) of ACS approximately 6 and 8 months after LentiGlobin gene therapy. The patient resumed chronic pRBC transfusions and hydroxyurea treatment and subsequently experienced 2 SAEs of vaso-occlusive pain; no additional SAEs of vaso-occlusive pain or ACS were reported during the last 16 months of follow-up after LentiGlobin infusion. The third SCD patient had no episodes of vaso-occlusive pain or ACS during 25.5 months of follow-up post-LentiGlobin gene therapy as of the data cut-off. Two patients with SCD who have been off chronic pRBC transfusions, showed improvement in hemolysis markers post-LentiGlobin treatment and stabilization of HbAT87Q expression at approximately 6 months post-LentiGlobin infusion. Total Hb levels for patients with SCD at last visit were 13.0 g/dL (patient 1), 9.4 g/dL (patient 2), and 9.8 g/dL (patient 3), with corresponding HbAT87Q contributions of 47.9%, 7.9%, and 25.8%, respectively.
Summary
With up to 5 years of follow-up, treatment with LentiGlobin gene therapy was well tolerated and resulted in improvement in hematologic parameters and disease-related symptoms. Further results from the completed study will be presented.
Display omitted
Hermine:Celgene: Research Funding; Novartis: Research Funding; AB science: Consultancy, Equity Ownership, Honoraria, Research Funding. Brousse:bluebird bio, Inc: Consultancy; AddMedica: Consultancy. El Nemer:Hemanext: Other: Other. Bartolucci:Novartis: Membership on an entity's Board of Directors or advisory committees; AddMedica: Honoraria, Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees; Agios: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; HEMANEXT: Membership on an entity's Board of Directors or advisory committees. Asmal:bluebird bio, Inc: Employment, Equity Ownership. Whitney:bluebird bio, Inc: Employment, Equity Ownership. Gayron:bluebird bio, Inc: Employment, Equity Ownership. Huang:bluebird bio, Inc.: Employment, Equity Ownership. de Montalembert:AddMedica: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; bluebird bio, Inc: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Ribeil:bluebird bio, Inc: Employment, Equity Ownership. Cavazzana:SmartImmune: Other: Founder.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Provider: - Institution: - Data provided by Europeana Collections- Date de numérisation : 2011- Nombre de vues du document : 510- Langue du document : Français- Lieu de publication : S.l.- Note : ...Emile Girardin, sculpteur du XIXe siècle est mentionné dans le Bénézit comme ayant reçu une mention au salon en 1891 ; Edme Gois (1765-1836) est le fils de Etienne Gois (1731-1823)- Note de contenu : Contient 2 photographies en noir et blanc signées et non datées reproduisant des statues de Grass ; Contient un croquis à la plume et au crayon non signé et daté de Joseph-Nicolas Guichard- Note complémentaire : Selon l’Allgemeines Künstlerlexikon, Benoit Lucien Hercule est né en 1846 ou 1848- Fonds ou documents en rapport : Original du Croquis à la plume et au crayon non signé de Joseph-Nicolas Guichard, non daté - Fonds ou documents en rapport : Original de la Lettre autographe signée de François Jouffroy, datée du 22 juin 1844, adressée à Antoine Louis Lacordaire, illustrée d'un croquis au crayon au verso - Partenariats : Document numérisé grâce au mécénat de la Société BIC- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: Institut National d'Histoire de l'Art - Data provided by Europeana Collections- 1613-1926- Nombre de vues du document : 510- Date de numérisation : 2011- Note : Emile ...Girardin, sculpteur du XIXe siècle est mentionné dans le Bénézit comme ayant reçu une mention au salon en 1891 ; Edme Gois (1765-1836) est le fils de Etienne Gois (1731-1823)- Note de contenu : Contient 2 photographies en noir et blanc signées et non datées reproduisant des statues de Grass ; Contient un croquis à la plume et au crayon non signé et daté de Joseph-Nicolas Guichard- Note complémentaire : Selon l’Allgemeines Künstlerlexikon, Benoit Lucien Hercule est né en 1846 ou 1848- Documents en rapport : Original du Croquis à la plume et au crayon non signé de Joseph-Nicolas Guichard, non daté- Documents en rapport : Original de la Lettre autographe signée de François Jouffroy, datée du 22 juin 1844, adressée à Antoine Louis Lacordaire, illustrée d'un croquis au crayon au verso- Partenariats : Document numérisé grâce au mécénat de la Société BIC- Langue du document : Français- Lieu de publication : S.l.- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: Österreichische Nationalbibliothek - Austrian National Library - Data provided by Europeana Collections- All metadata published by Europeana are available free of restriction ...under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain ...Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
PDF